Login to Your Account

Earnings Roundup

Friday, October 21, 2011
• Alexion Pharmaceuticals Inc., of Cheshire, Conn., reported third-quarter revenues of $204 million, besting analyst estimates of $198.9 million, thanks to higher sales of paroxysmal nocturnal hemoglobinuria drug Soliris (eculizumab). Net income totaled $72.6 million, or 34 cents per share, compared to consensus estimates of 29 cents per share. In September, Soliris gained approval for a second orphan indication, atypical hemolytic uremic syndrome. Alexion ended the third quarter with about $445.2 million in cash, equivalents and marketable securities. The company's stock (NASDAQ:ALXN) closed Thursday at $66.25, up 19 cents. (See BioWorld Today, Sept. 26, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription